Theravance Biopharma/$TBPH

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Theravance Biopharma

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Ticker

$TBPH
Primary listing

Industry

Pharmaceuticals

Employees

97

ISIN

KYG8807B1068

TBPH Metrics

BasicAdvanced
$565M
-
-$1.19
-0.10
-

What the Analysts think about TBPH

Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.

Bulls say / Bears say

Theravance Biopharma achieved record YUPELRI® (revefenacin) net sales of $66.7 million in Q4 2024, marking a 10% year-over-year increase, indicating strong market demand and effective commercialization strategies. (Theravance Biopharma News Release)
The company received a $50 million milestone payment from GSK due to TRELEGY's net sales reaching $3.46 billion in 2024, reflecting the product's robust performance and contributing significantly to Theravance's revenue stream. (Theravance Biopharma News Release)
Theravance's strategic sale of its remaining royalty interest in TRELEGY to GSK for $225 million in June 2025 has bolstered its cash reserves, providing financial flexibility for future investments and shareholder returns. (Theravance Biopharma News Release)
Theravance reported a GAAP net loss of $13.6 million in Q1 2025, an increase from the $11.7 million loss in Q1 2024, indicating ongoing financial challenges despite revenue growth. (Theravance Biopharma News Release)
The company's ampreloxetine program faced delays, with final patient enrollment in the CYPRESS study pushed to mid-2025, potentially postponing revenue generation from this pipeline candidate. (Theravance Biopharma News Release)
Theravance underwent a 17% workforce reduction in February 2023, reflecting operational challenges and potential impacts on future research and development capabilities. (BioPharma Dive)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

TBPH Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TBPH Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TBPH

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs